Sangamo Biosciences (SGMO) has disclosed a new risk, in the Manufacturing category. Sangamo Biosciences does not face any business risks ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Sangamo Biosciences (SGMO – Research Report) today and set a price target of $10.00. Patrick Trucchio’s rating is based on Sangamo ...

RBC Capital Mkts has recently reduced Sangamo Therapeutics Inc (SGMO) stock to Sector Perform rating, as announced on November 3, 2023, according to Finviz. Earlier, on April 28, 2023, BofA Securities ...

Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

CHICAGO — The former chief lobbyist for electric utility Commonwealth Edison has spent the last week telling a federal jury ...

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

Sangamo Therapeutics SGMO is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

On Friday, Sangamo Therapeutics Inc (SGMO) stock saw a modest uptick, ending the day at $2.87 which represents a slight increase of $0.06 or 2.14% from the prior close of $2.81. The stock opened at $2 ...